CliffBio
biologic

Yervoy

ipilimumab

Loss of exclusivityMarch 2023projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb Company →See this company's full patent-cliff portfolio

Drug detail

Brand nameYervoy
Active ingredientipilimumab
Strength50MG/10ML (5MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2011
Marketing statusRx

More from Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Yervoy patent cliff — loss of exclusivity March 2023 | CliffBio